Nurix Therapeutics Inc (NRIX)

07:48 AM

(NRIX) Trading Signals - news.stocktradersdaily.com

07:48 AM

03:40 AM

JPMorgan Chase & Co. Reduces Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

03:40 AM

May 01, 2025

Nurix Therapeutics (NASDAQ:NRIX) Receives "Buy" Rating from Needham & Company LLC - MarketBeat

May 01, 2025

May 01, 2025

Darwin Global Management Ltd. Takes $3.08 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

May 01, 2025

May 01, 2025

Price T Rowe Associates Inc. MD Lowers Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

May 01, 2025

Apr 30, 2025

Nurix therapeutics’ chief scientific officer sells $38,841 in stock By Investing.com - Investing.com Canada

Apr 30, 2025

Apr 30, 2025

Nurix therapeutics’ chief scientific officer sells $38,841 in stock - Investing.com

Apr 30, 2025

Apr 30, 2025

Nurix Therapeutics Executives Sell Shares for Tax Obligations - TradingView

Apr 30, 2025

Apr 30, 2025

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Purchased by Lord Abbett & CO. LLC - MarketBeat

Apr 30, 2025

Apr 30, 2025

T. Rowe Price Investment Management Inc. Sells 167,663 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Apr 30, 2025

Apr 29, 2025

Breaking Down Nurix Therapeutics: 7 Analysts Share Their Views - Benzinga

Apr 29, 2025

Apr 28, 2025

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs - The Manila Times

Apr 28, 2025

Apr 28, 2025

Russell Investments Group Ltd. Grows Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Apr 28, 2025

Apr 26, 2025

Nurix Therapeutics (NASDAQ:NRIX) Stock Price Up 6.4%Here's Why - MarketBeat

Apr 26, 2025

Apr 26, 2025

Nurix Therapeutics reports breakthroughs in cancer drug research - Investing.com Australia

Apr 26, 2025

Apr 25, 2025

Jump Financial LLC Purchases New Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Apr 25, 2025

Apr 25, 2025

Nurix Therapeutics Presents Positive Preclinical Data at the AAC - GuruFocus

Apr 25, 2025

Apr 25, 2025

Nurix Therapeutics Showcases Promising Preclinical Data for BTK, BRAF, and Aurora A Kinase Degraders at AACR 2025 Annual Meeting - Nasdaq

Apr 25, 2025

Apr 25, 2025

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets - The Manila Times

Apr 25, 2025

Apr 25, 2025

Revolutionary Brain-Penetrant Cancer Drugs Outperform Competitors: 10,000 Proteins Destroyed Per Hour - Stock Titan

Apr 25, 2025

Apr 25, 2025

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $30.44 Average Price Target from Analysts - MarketBeat

Apr 25, 2025

Apr 22, 2025

Geode Capital Management LLC Acquires 137,087 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Apr 22, 2025

Apr 21, 2025

Nurix Therapeutics (NASDAQ:NRIX) Shares Gap DownWhat's Next? - MarketBeat

Apr 21, 2025

Apr 20, 2025

Affinity Asset Advisors LLC Raises Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Apr 20, 2025

Apr 19, 2025

Wasatch Advisors LP Lowers Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Apr 19, 2025

Apr 19, 2025

Fmr LLC Grows Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Apr 19, 2025

Apr 18, 2025

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Trexquant Investment LP - MarketBeat

Apr 18, 2025

Apr 18, 2025

(NRIX) Technical Data - news.stocktradersdaily.com

Apr 18, 2025

Apr 17, 2025

Nurix advances IRAK4 degrader into Phase 1 trials with FDA nod - Investing.com Canada

Apr 17, 2025

Apr 17, 2025

Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential - Seeking Alpha

Apr 17, 2025

Apr 17, 2025

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher - simplywall.st

Apr 17, 2025

Apr 17, 2025

Nurix advances IRAK4 degrader into Phase 1 trials with FDA nod By Investing.com - Investing.com South Africa

Apr 17, 2025

Apr 17, 2025

Nurix Therapeutics (NRIX) Advances Experimental Drug Following FDA Clearance - GuruFocus

Apr 17, 2025

Apr 17, 2025

Nurix gets FDA clearance to initiate trial for its anti-inflammatory drug candidate - Seeking Alpha

Apr 17, 2025

Apr 17, 2025

FDA Clears IND for Nurix's (NRIX) IRAK4 Degrader, Phase 1 Trial Set for 2025 | NRIX Stock News - GuruFocus

Apr 17, 2025

Apr 17, 2025

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479a Novel IRAK4 Degrader for Inflammatory Conditions - The Manila Times

Apr 17, 2025

Apr 17, 2025

Nurix Therapeutics Announces FDA Clearance for GS-6791/NX-0479 IND, Phase 1 Trials Set to Begin in Q2 2025 in Collaboration with Gilead Sciences - Nasdaq

Apr 17, 2025

Apr 17, 2025

FDA Green Lights Groundbreaking IRAK4 Degrader: $420M Milestone Potential in Inflammatory Disease Fight - Stock Titan

Apr 17, 2025

Apr 16, 2025

Leerink Partnrs Has Optimistic Outlook of NRIX Q2 Earnings - MarketBeat

Apr 16, 2025

Apr 15, 2025

Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates - MSN

Apr 15, 2025

Apr 15, 2025

NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program - MSN

Apr 15, 2025

Apr 15, 2025

Vanguard Group Inc. Boosts Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Apr 15, 2025

Apr 15, 2025

Norges Bank Makes New $6.01 Million Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Apr 15, 2025